Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.

@article{LeckaCzernik2007ActivationOP,
  title={Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo.},
  author={Beata Lecka-Czernik and Cheryl L. Ackert-Bicknell and Martin L. Adamo and V. Marmolejos and Gary A. Churchill and Keith R. Shockley and Ian R Reid and Andrew Grey and Clifford J. Rosen},
  journal={Endocrinology},
  year={2007},
  volume={148 2},
  pages={903-11}
}
Rosiglitazone (Rosi) belongs to the class of thiazolidinediones (TZDs) that are ligands for peroxisome proliferator-activated receptor gamma (PPARgamma). Stimulation of PPARgamma suppresses bone formation and enhances marrow adipogenesis. We hypothesized that activation of PPARgamma down-regulates components of the IGF regulatory system, leading to impaired osteoblast function. Rosi treatment (1 microm) of a marrow stromal cell line (UAMS-33) transfected with empty vector (U-33/c) or with… CONTINUE READING